PPARA and metabolic syndrome: The proteomics analysis revealed that the PPARα-signaling pathway is the underlying mechanism of Torularhodin’s anti-hepatic dyslipidemia effect, which is consistent with the literature report on the function of PPARα on dyslipidemia [35] and further supported by a recent report on the occurrence of MAFLD after the hepatocyte-specific Pparα was deleted [36].